These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 31070988)

  • 1. Serum IgG antibodies to
    Cohen D; Meron-Sudai S; Bialik A; Asato V; Goren S; Ariel-Cohen O; Reizis A; Hochberg A; Ashkenazi S
    Hum Vaccin Immunother; 2019; 15(6):1401-1408. PubMed ID: 31070988
    [No Abstract]   [Full Text] [Related]  

  • 2. Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection.
    Talaat KR; Alaimo C; Martin P; Bourgeois AL; Dreyer AM; Kaminski RW; Porter CK; Chakraborty S; Clarkson KA; Brubaker J; Elwood D; Frölich R; DeNearing B; Weerts H; Feijoo BL; Halpern J; Sack D; Riddle MS; Fonck VG
    EBioMedicine; 2021 Apr; 66():103310. PubMed ID: 33862589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repertoire of Naturally Acquired Maternal Antibodies Transferred to Infants for Protection Against Shigellosis.
    Ndungo E; Andronescu LR; Buchwald AG; Lemme-Dumit JM; Mawindo P; Kapoor N; Fairman J; Laufer MK; Pasetti MF
    Front Immunol; 2021; 12():725129. PubMed ID: 34721387
    [No Abstract]   [Full Text] [Related]  

  • 4. Functional and Antigen-Specific Serum Antibody Levels as Correlates of Protection against Shigellosis in a Controlled Human Challenge Study.
    Shimanovich AA; Buskirk AD; Heine SJ; Blackwelder WC; Wahid R; Kotloff KL; Pasetti MF
    Clin Vaccine Immunol; 2017 Feb; 24(2):. PubMed ID: 27927680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune response characterization in a human challenge study with a Shigella flexneri 2a bioconjugate vaccine.
    Clarkson KA; Talaat KR; Alaimo C; Martin P; Bourgeois AL; Dreyer A; Porter CK; Chakraborty S; Brubaker J; Elwood D; Frölich R; DeNearing B; Weerts HP; Feijoo B; Halpern J; Sack D; Riddle MS; Fonck VG; Kaminski RW
    EBioMedicine; 2021 Apr; 66():103308. PubMed ID: 33813141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Threshold protective levels of serum IgG to Shigella lipopolysaccharide: re-analysis of Shigella vaccine trials data.
    Cohen D; Ashkenazi S; Schneerson R; Farzam N; Bialik A; Meron-Sudai S; Asato V; Goren S; Baran TZ; Muhsen K; Gilbert PB; MacLennan CA
    Clin Microbiol Infect; 2023 Mar; 29(3):366-371. PubMed ID: 36243351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assembly, Biochemical Characterization, Immunogenicity, Adjuvanticity, and Efficacy of
    Turbyfill KR; Clarkson KA; Vortherms AR; Oaks EV; Kaminski RW
    mSphere; 2018; 3(2):. PubMed ID: 29600284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shigella-specific antibodies in the first year of life among Zambian infants: A longitudinal cohort study.
    Chisenga CC; Bosomprah S; Simuyandi M; Mwila-Kazimbaya K; Chilyabanyama ON; Laban NM; Bialik A; Asato V; Meron-Sudai S; Frankel G; Cohen D; Chilengi R
    PLoS One; 2021; 16(5):e0252222. PubMed ID: 34043697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Shigella conjugate vaccine targeting Shigella flexneri 6 that is immunogenic and provides protection against virulent challenge.
    Kelly M; Janardhanan J; Wagh C; Verma S; Charles RC; Leung DT; Kamruzzaman M; Pansuriya RK; Chowdhury F; Vann WF; Kaminski RW; Khan AI; Bhuiyan TR; Qadri F; Kováč P; Xu P; Ryan ET
    Vaccine; 2024 Oct; 42(24):126263. PubMed ID: 39217775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional antibodies as immunological endpoints to evaluate protective immunity against
    Ndungo E; Pasetti MF
    Hum Vaccin Immunother; 2020; 16(1):197-205. PubMed ID: 31287754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shigella outer membrane protein PSSP-1 is broadly protective against Shigella infection.
    Kim JO; Rho S; Kim SH; Kim H; Song HJ; Kim EJ; Kim RY; Kim EH; Sinha A; Dey A; Yang JS; Song MK; Nandy RK; Czerkinsky C; Kim DW
    Clin Vaccine Immunol; 2015 Apr; 22(4):381-8. PubMed ID: 25651919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G.
    Clarkson KA; Frenck RW; Dickey M; Suvarnapunya AE; Chandrasekaran L; Weerts HP; Heaney CD; McNeal M; Detizio K; Parker S; Hoeper A; Bourgeois AL; Porter CK; Venkatesan MM; Kaminski RW
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32968012
    [No Abstract]   [Full Text] [Related]  

  • 13.
    Clarkson KA; Porter CK; Talaat KR; Frenck RW; Alaimo C; Martin P; Bourgeois AL; Kaminski RW
    mSphere; 2021 Aug; 6(4):e0012221. PubMed ID: 34259559
    [No Abstract]   [Full Text] [Related]  

  • 14. In silico analysis to identify vaccine candidates common to multiple serotypes of Shigella and evaluation of their immunogenicity.
    Pahil S; Taneja N; Ansari HR; Raghava GPS
    PLoS One; 2017; 12(8):e0180505. PubMed ID: 28767653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mapping the functional B-cell epitopes of
    Li S; Zhang W
    Appl Environ Microbiol; 2024 Aug; 90(8):e0098824. PubMed ID: 39082807
    [No Abstract]   [Full Text] [Related]  

  • 16. A Novel
    Ndungo E; Randall A; Hazen TH; Kania DA; Trappl-Kimmons K; Liang X; Barry EM; Kotloff KL; Chakraborty S; Mani S; Rasko DA; Pasetti MF
    mSphere; 2018 Aug; 3(4):. PubMed ID: 30068560
    [No Abstract]   [Full Text] [Related]  

  • 17. Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypes.
    Heine SJ; Diaz-McNair J; Andar AU; Drachenberg CB; van de Verg L; Walker R; Picking WL; Pasetti MF
    J Immunol; 2014 Feb; 192(4):1630-40. PubMed ID: 24453241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.
    Levine MM; Kotloff KL; Barry EM; Pasetti MF; Sztein MB
    Nat Rev Microbiol; 2007 Jul; 5(7):540-53. PubMed ID: 17558427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral immunization with LacVax® OmpA induces protective immune response against Shigella flexneri 2a ATCC 12022 in a murine model.
    Yagnik B; Sharma D; Padh H; Desai P
    Vaccine; 2019 May; 37(23):3097-3105. PubMed ID: 31047673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I trial of WRSS1, a
    Raqib R; Sarker P; Zaman K; Alam NH; Wierzba TF; Maier N; Talukder K; Baqui AH; Suvarnapunya AE; Qadri F; Walker RI; Fix A; Venkatesan MM
    Hum Vaccin Immunother; 2019; 15(6):1326-1337. PubMed ID: 30794051
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.